Mutations in UMOD Contribute to the Pathogenesis of ADTKD ‐ UMOD by Influencing the Function of Complement Factor H
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Qiuyu Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Uromodulin, Complement Factor H, Mutation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Tubular atrophy and interstitial fibrosis are basic renal pathological changes in autosomal dominant tubulointerstitial kidney disease (ADTKD). Reduced secretion or abnormal structure of uromodulin (UMOD) are recognised pathogenic factors of ADTKD. Studies show uromodulin binds complement factor H (cFH), enhancing its ability to inhibit complement activation. Overactivation of the complement system contributes to tubulointerstitial injury. Therefore, exploring the UMOD–tubulointerstitial fibrosis link may aid in the development of treatment for ADTKD‐UMOD. Immunofluorescence staining detected complement deposition in patients' kidneys. Uromodulin's binding affinity for cFH was assessed using microthermophoresis. The effect of this binding on cFH function was analysed using C3b degradation and erythrocyte hemolysis tests. Recombinant wild‐type and mutant uromodulin proteins were expressed and tested using the aforementioned methods. Complement factor B was detected in the kidneys of patients with ADTKD‐UMOD. Patient‐derived uromodulin showed reduced binding to cFH and decreased capacity to assist in C3b cleavage and hemolysis inhibition. Recombinant wild‐type uromodulin significantly enhanced C3b cleavage ( p < 0.001) and inhibited hemolysis ( p < 0.01). Uromodulin mutants showed reduced binding to cFH and limited ability to promote C3b degradation, with no significant hemolysis inhibition. Impaired interactions between mutants and cFH may lead to insufficient inhibition of complement activity, triggering tubulointerstitial fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Division, Peking University First Hospital, Beijing, China.
- Institute of Nephrology, Peking University, Beijing, China.
- Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
- Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.
- Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
- Joint International Research Center of Translational and Clinical Research, Beijing, China.
ORCID-Profile: Yuqing Chen
Förderung
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Xie, Q., Bai, L., Gong, K., Hu, N., & Chen, Y. (2026). Mutations in UMOD Contribute to the Pathogenesis of ADTKD ‐ UMOD by Influencing the Function of Complement Factor H. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71025
Vancouver
Xie Q, Bai L, Gong K, Hu N, Chen Y. Mutations in UMOD Contribute to the Pathogenesis of ADTKD ‐ UMOD by Influencing the Function of Complement Factor H. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71025
BibTeX
@article{Xie2026,
author = {Xie, Qiuyu and Bai, Lufeng and Gong, Kunjing and Hu, Nan and Chen, Yuqing},
title = {Mutations in UMOD Contribute to the Pathogenesis of ADTKD ‐ UMOD by Influencing the Function of Complement Factor H},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71025}
}
EUVIMED